15 Months of Progress After 15 months of consistent treatment with Tirzepatide at a dose of 7.5 mg/week, JHs results were nothing short of inspiring: Follow-Up Bioimpedance Spectroscopy Measurements: Weight: 162 lbs (a 78-lb loss) Body Fat Percentage: 32.9% (down 12.8%) BMI: 23.3 (a reduction of 10.1 kg/m) Body Fat Mass: 53.2 lbs (a decrease of 56 lbs) Lean Body Mass: 109 lbs (down 21 lbs) Skeletal Muscle Mass: 59 lbs (loss of only 12 lbsjust 15% of her total weight loss, less than the typical 20%) ECW/TBW: Slight improvement in the right leg to 0.396
[1] Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue, meaning that it mimics the naturally-occuring GLP-1 hormone to stabilise blood sugar levels, stimulate satiety and in turn, encourage weight loss
After your free consultation, baseline labs typically return within 3 to 5 business days
Many providers recommend 68 week intervals between dose increases to give your body time to adapt
The move signals a strategic pivot, Novo Nordisk is not only aiming to keep its dominant position in the obesity and diabetes markets, but also proactively responding to mounting pressures from intense patient demand to safety concerns around compounded semaglutide alternatives and the broader political push for price reductions across chronic-disease therapies
Yes weight is one BUT IYKYK its a lot of things that comes with PCOS that can and is a burden